chronic kidney disease

Providing health services in the community offers benefits to patients and can be more efficient for health systems. This was true long before any of us had heard of COVID-19, but the pandemic has highlighted the need to provide safe and effective community and home care for vulnerable patients, like those suffering from chronic kidney disease (CKD) and needing kidney replacement therapy (KRT ). By 2030, if no action is taken, the number of CKD patients could reach 14.5 million . This imposes a heavy burden on patients and their families, but also translates into significant costs for health systems: treatment for CKD accounts for 2% of many countries' healthcare budgets. While investing in preventative measures and research for kidney disease is important, we also need to provide all treatment options as part of the continuum of care to allow patients to live well with CKD. Our goal should be to embrace a shared decision-making approach and take advantage of the new opportunities provided by digital solutions for remote treatment and patient support, particularly in the context of COVID-19. This concept is reflected in the theme of this year's World Kidney Day : Health for Everyone Everywhere: Living Well with Kidney Disease. COVID-19 risk factors Research shows that CKD is one of the most prevalent risk factors for severe COVID-19 . In light of this, the European Kidney Health Alliance has issued a Call to Action supported by the European Commissioner for Health, Stella Kyriakides, and endorsed by 20 Members of the European Parliament and 69 scientific & patient organisations from across Europe. It demands better access to home therapies, transplantation and the uptake of digital tools, as well as better prevention, research, collection and sharing of CKD data. The European Commission's Expert Panel on Resilient Health & Social Care...
This blog is part of the Early Diagnosis campaign #BeFirst Early diagnosis and care can prevent illness from developing and slow disease progression. Lab tests, genetic tests, tests for chronic diseases and modern lab diagnostics can help facilitate earlier intervention and improves outcomes for patients and are increasingly valuable in informing treatment choice. Read the other blogs here: Why should we prevent cervical cancer? Because we can , A smarter way to fight colorectal cancer , Can screening decrease lung cancer mortality rates? , For kidney disease patients, treatment education and choice are key to better outcomes , Diagnosing severe hearing loss and deafness ****************************************** Chronic kidney disease is a major concern for healthcare providers worldwide. Tests that allow efficient and accurate diagnosis are vital. We all know someone living with chronic kidney disease (CKD) – even if they have not yet been diagnosed: it is estimated that 10 percent of the global population is affected by CKD 1 . Between 1990 and 2010, kidney disease became one of the fastest-growing causes of death in the world, second only to HIV/AIDS. 1 Reviewing the data on CKD diagnosis, we were struck by how timely detection can impact patient outcomes. Catching kidney disease in the early stages is a challenge, since there are typically no overt signs or symptoms. However, if CKD is detected early and managed appropriately, the deterioration in kidney function can be slowed and the risk of associated cardiovascular complications reduced. 2 For patients, this can make all the difference, but we know too that there is a real impact for health systems where demand is rising and resources may be scarce. CKD also represents more than €1 trillion in healthcare costs over the next decade. 3 Key indicators of kidney function So, what are the tell-tale signs...
This blog is part of the Early Diagnosis campaign #BeFirst Early diagnosis and care can prevent illness from developing and slow disease progression. Lab tests, genetic tests, tests for chronic diseases and modern lab diagnostics can help facilitate earlier intervention and improves outcomes for patients and are increasingly valuable in informing treatment choice. Read the other blogs here: A smarter way to fight colorectal cancer , Why should we prevent cervical cancer? Because we can , Diagnosing severe hearing loss and deafness , Can screening decrease lung cancer mortality rates? and Kidney Disease: catch it early to save lives and money . *************************************************** To me, modern healthcare should be about improving patient outcomes and offering patients as much choice as possible. All of us are patients at certain times in our lives. Shouldn’t we have greater input into how and where we are treated? When it comes to kidney disease, not all patients have time to consider their options and prepare for treatment. To understand why this is, let me explain a little about the condition. Kidney disease is a major and growing burden in Europe . One in ten Europeans has some form of kidney disease but most don’t know it . However, kidney failure is a ‘silent disease’, often diagnosed in the late stages. This significantly narrows the treatment options available to patients, often leading to worse outcomes. For some, late diagnosis denies them the opportunity to learn about and to discuss home dialysis with their doctors. Clinical guidelines – such as the NICE clinical guidance on peritoneal dialysis –recommend that stage 5 chronic kidney disease patients should be informed of all treatment options so that they can choose the one that best fits their lifestyle. Time to explore treatment options The best treatment for kidney failure is...
A new report on Laboratory Medicine in Poland highlights the role of laboratory diagnostics in the timely treatment of chronic conditions. Not only can investment in early diagnosis save and improve lives, it can also save money on long-term care. ‘There is not enough data on how health budgets are spent,’ says Jozef Jakubiec, Director General of IPDDL which compiled the report with Deloitte. ‘We wanted to show hard evidence to illustrate to decision-makers that that situation in Poland is considerably worse than in neighbouring countries, such as the Czech Republic.’ Take diabetes, for example. Serious complications from the advanced stages of the condition can include chronic kidney disease (CKD). This, in turn, may lead to a life-long dialysis or kidney transplantation – both of which come at a considerable personal and economic cost. Some people live with diabetes mellitus without symptoms for many years. Indeed, it may not be until complications arise that their condition is diagnosed. However, by that stage considerable damage may have been done. Even small changes in blood glucose can begin the process of degeneration of blood vessels. In order to intervene early and with the right treatment, glucose testing is essential. If Poland were to increase glucose testing by 25% a year, savings of PLN 0.5 billion (€0.12 billion) would be made within six years. For patients with diabetes-related conditions, the annual cost was estimated at PLN 5 (€1.17) in pre-diabetes compared to PLN 9,269 (€2,168) in diabetes with complications (an over 1800-fold difference). ‘The earlier the treatment is taken and monitored regularly, the more effective and less expensive it is,’ the report says. Prevention is cheaper than cure For CKD, it’s a similar story: the disease may remain asymptomatic until the last stage of renal failure. ‘There’s a big shift towards CKD because...